Report Company Directory

Dechra Pharmaceuticals PLC

• DECHRA PHARMACEUTICALS : coverage dropped by BNP Paribas
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG
• Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc by EQS Group AG

DECHRA PHARMACEUTICALS PLC

• European Equity Strategy: Muddle through – June Chart Pack by Barclays

Decibel Therapeutics

• Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update by GlobeNewsWire
• U.S. Small & Mid Cap Biotechnology: Discontinuing Coverage by Barclays
• ASCO 2023 Takeaways - Compiled by Barclays
• Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference by GlobeNewsWire
• Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting by GlobeNewsWire
• Gena-editing: Monthly Recap - May 2023 by Barclays
• U.S. Small & Mid Cap Biotechnology: Key takeaways from Barclays Gene Editing & Gene Therapy Summit by Barclays
• Gena-typing: Week of 05/15/2023 by Barclays
• ASGCT 2023 Takeaways - Day 4 by Barclays
• ASGCT 2023 Takeaways - Day 2 by Barclays

DECILLION FINANCE LTD

Decimal Software

• Insider bought: A director bought 870,000 shares at 0.057AUD and by SmartInsider
• Ford Equity International Rating and Forecast Report by Ford Equity Research